David A. Siegel 4 D Molecular Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q3 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in 4 D Molecular Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 22,900 shares of FDMT stock, worth $127,095. This represents 0.0% of its overall portfolio holdings.
Number of Shares
22,900Holding current value
$127,095% of portfolio
0.0%Shares
5 transactions
Others Institutions Holding FDMT
# of Institutions
144Shares Held
57.7MCall Options Held
137KPut Options Held
111K-
Bvf Inc San Francisco, CA7.38MShares$41 Million2.54% of portfolio
-
Ra Capital Management, L.P. Boston, MA5.1MShares$28.3 Million0.77% of portfolio
-
Black Rock Inc. New York, NY4.9MShares$27.2 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY4.4MShares$24.4 Million4.93% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.1MShares$22.7 Million1.63% of portfolio
About 4D Molecular Therapeutics, Inc.
- Ticker FDMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 32,382,400
- Market Cap $180M
- Description
- 4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical tr...